Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Bone Cancer

sorafenib has been researched along with Bone Cancer in 67 studies

Research

Studies (67)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (10.45)29.6817
2010's51 (76.12)24.3611
2020's9 (13.43)2.80

Authors

AuthorsStudies
Deng, Y; Dong, S; Han, W; Han, Y; Li, Z; Liu, S; Luo, Z; Ni, D; Niu, L; Pi, R; Song, L; Sun, D; Wei, Q; Zhao, Y; Zhu, T1
Hu, X; Jian, C; Li, D; Li, P; Li, Y; Li, Z; Yi, W; Yu, A; Yuan, Y; Zhao, Y1
Huyan, T; Lou, C; Shang, P; Wang, S; Zhang, H1
Yang, YT; Yuzbasiyan-Gurkan, V1
Bao, Q; Hu, F; Liu, Z; Wang, J; Wen, J; Yu, P; Zhang, W1
Arakawa, A; Iwata, S; Kawai, A; Kobayashi, E; Kumamoto, T; Maniwa, J; Nakajima, M; Ogawa, C; Shirakawa, N; Sugiyama, M; Tanimura, K; Tao, K; Watanabe, Y; Yoneda, A1
Albersen, M; Baldewijns, M; Beuselinck, B; Bourgain, C; Debruyne, PR; Haaker, L; Laenen, A; Laguerre, B; Lerut, E; Oudard, S; Renders, I; Rioux-Leclercq, N; Roussel, E; Tryssesoone, L; Van den Bulck, H; Verbiest, A; Wynendaele, W1
Fu, BS; Hsu, FT; Lin, KH; Pan, PJ; Tsai, JJ; Weng, MC; Wu, CH1
DeVere White, RW; Duan, Z; Ho, PY; Jian, C; Lam, KS; Lara, PN; Qiu, JX; Tu, MJ; Wun, T; Yu, AM; Yu, AX; Zhang, Q1
García Carretero, R; Rebollo-Aparicio, N; Romero Brugera, M; Vazquez-Gomez, O1
Bilska, K; Raciborska, A1
Armstrong, AE; Leavey, PJ; Reichek, J; Walterhouse, DO; Walz, AL1
Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N1
Celine, J; Couvreur, K; Frederic, D; Marlies, B; Philippe, D; Randal, D; Sylvie, R1
Jiang, W; Zeng, ZC1
Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E1
Haraldsdottir, S; Ing, SW; Kendra, K; Li, Q; Olencki, TE; Villalona-Calero, MA1
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T1
Natori, T; Yamaguchi, M1
Burger, S; Gallè, B; Mair, G; Miller, I; Steinborn, R; Walter, I; Wolfesberger, B1
Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R1
Pitoia, F1
Black, EP; Karabakhtsian, RG; Massarweh, S; Moss, J; Napier, D; Romond, E; Slone, S; Wang, C; Weiss, H1
Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A1
Bode, B; Cathomas, R; Fuchs, B; Rothermundt, C; Schwitter, M; von Moos, R1
Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J1
Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U1
Albiges, L; Escudier, B1
Chun, HG; Chun, HJ; Hong, SH; Hwang, SW; Jung, ES; Lee, JE; Lee, JM; Lee, MA; Lee, SH1
Chang, B; Chen, JC; Chiang, IT; Hsu, FT; Hwang, JJ; Kwang, WK; Liu, YC1
Cai, Y; Li, H; Li, Y; Wang, K; Zhang, Y1
Brüssow, C; Guckenberger, M; Pestalozzi, B; Riesterer, O; Stieb, S; Weiler, S1
Dinçaslan, H; Ensari, A; Kiremitçi, S; Özçakar, ZB; Taktak, A; Yalçınkaya, F; Yılmaz, S1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R1
Hong, TH; Kim, DG; Na, GH; You, YK1
Fountas, A; Giotaki, Z; Kalogeropoulos, CD; Tigas, S; Tsatsoulis, A1
Chishima, T; Dry, SM; Eilber, FC; Elliott, I; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Nelson, SD; Russell, T; Singh, A; Tanaka, K; Yanagawa, J; Zhang, Y; Zhao, M1
Chung, J; Hong, SH; Joo, KJ; Kim, CS; Kim, S; Kim, SH; Kim, TN; Kwak, C; Kwon, TG; Lee, SE; Nam, BH; Seo, IY; Seo, SI; Song, K1
Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Draper, D; Figg, WD; Gulley, JL; Jain, L; Jones, E; Steinberg, SM; Venitz, J; Wright, JJ1
Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K1
Egerbacher, M; Gerner, W; Heiduschka, G; Skalicky, M; Thalhammer, JG; Tonar, Z; Walter, I; Wolfesberger, B1
Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J1
Dudek, AZ; Franklin, MJ; Spector, E; Truskinovsky, AM1
Corssmit, EP; Gelderblom, H; Heemstra, KA; Hoftijzer, H; Huijberts, M; Kapiteijn, E; Morreau, H; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Weijers, K1
Hasegawa, Y; Matsubara, A; Mita, K; Ohdan, H1
Furukawa, M; Hakariya, T; Ide, S; Ishimoto, H; Kohno, S; Nagashima, S; Nakamura, Y; Sawai, T; Soda, H; Takemoto, S; Tomari, S1
Antón-Torres, A; Bellmunt, J; Carles, J; Guillem, V; López-Martín, JA; Maroto-Rey, P; Trigo, JM; Urruticoechea, L1
Guo, W; Lu, X; Ren, T; Tang, X; Zhao, H1
Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S1
Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ1
Behnsawy, HM; Fujisawa, M; Fukuhara, T; Inoue, TA; Kusuda, Y; Miyake, H1
Boeykens, E; Rutsaert, R; Stappaerts, I; Van Loo, S1
Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F1
Bihari, C; Gupta, NL; Jain, D; Rastogi, A; Sarin, SK1
Anderson, BE; Mackay, D; Svoboda, RM; Welsch, MJ1
Arai, Y; Kawashima, A; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M1
Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E1
Saito, K1
Boni, C; Bracarda, S; Caserta, C; Cinquini, M; Cortesi, E; De Angelis, V; Di Costanzo, F; Falcone, A; Gasparro, D; Labianca, R; Mucciarini, C; Paglino, C; Pazzola, A; Porta, C; Santoro, A1
Puche-Sanz, I; Vázquez-Alonso, F1
Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P1
Hara, J; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Seike, K; Takagi, Y1
Autran Gomez, AM; Di Silverio, F; Gentile, V; Gentilucci, A; Parente, U; Salciccia, S; Sciarra, A1
Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P1
Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E1

Reviews

4 review(s) available for sorafenib and Bone Cancer

ArticleYear
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
    International journal of molecular sciences, 2019, Jan-04, Volume: 20, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin

2019
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
    Anti-cancer drugs, 2013, Volume: 24, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid

2013
Radiation recall dermatitis induced by sorafenib : A case study and review of the literature.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2016, Volume: 192, Issue:5

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiodermatitis; Radiotherapy, Conformal; Sorafenib; Treatment Outcome

2016
Classic biphasic pulmonary blastoma: a case report and review of the literature.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Fatal Outcome; Humans; Intestinal Perforation; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pulmonary Blastoma; Pyridines; Sorafenib

2011

Trials

8 trial(s) available for sorafenib and Bone Cancer

ArticleYear
Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.
    Future oncology (London, England), 2014, Volume: 10, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Receptors, Estrogen; Sorafenib; Tamoxifen; Treatment Outcome

2014
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Intention to Treat Analysis; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Niacinamide; Osteosarcoma; Phenylurea Compounds; Sirolimus; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult

2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib

2015
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
    BJU international, 2009, Volume: 103, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Orchiectomy; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; raf Kinases; Soft Tissue Neoplasms; Sorafenib; Treatment Outcome

2009
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
    European journal of endocrinology, 2009, Volume: 161, Issue:6

    Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms

2009
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib

2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    American journal of clinical oncology, 2011, Volume: 34, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome

2011
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
    European urology, 2013, Volume: 63, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Recombinant Proteins; Sorafenib; Treatment Outcome

2013

Other Studies

55 other study(ies) available for sorafenib and Bone Cancer

ArticleYear
Novel 2-phenyl-3-(Pyridin-2-yl) thiazolidin-4-one derivatives as potent inhibitors for proliferation of osteosarcoma cells in vitro and in vivo.
    European journal of medicinal chemistry, 2022, Jan-15, Volume: 228

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Osteosarcoma; Pyridines; Structure-Activity Relationship; Thiazolidines

2022
Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model.
    Medical oncology (Northwood, London, England), 2022, Apr-28, Volume: 39, Issue:5

    Topics: Aminopyridines; Animals; Benzamides; Bone Neoplasms; Cell Line, Tumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Mice; Osteosarcoma; Sorafenib

2022
12 T high static magnetic field suppresses osteosarcoma cells proliferation by regulating intracellular ROS and iron status.
    Experimental cell research, 2022, 08-15, Volume: 417, Issue:2

    Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Humans; Iron; Magnetic Fields; Osteosarcoma; Reactive Oxygen Species; Sorafenib

2022
Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.
    International journal of molecular sciences, 2022, Aug-19, Volume: 23, Issue:16

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Cell Line; Cell Line, Tumor; Cisplatin; Dog Diseases; Dogs; Doxorubicin; Humans; Osteosarcoma; Sorafenib

2022
Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:8

    Topics: Animals; B7-H1 Antigen; Bone Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Doxorubicin; Humans; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Osteosarcoma; Sorafenib; Tumor Microenvironment; Up-Regulation

2023
Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:7

    Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Everolimus; Female; Humans; Male; Neoplasm Recurrence, Local; Osteosarcoma; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tyrosine Kinase Inhibitors; Young Adult

2023
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
    Urologic oncology, 2020, Volume: 38, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome

2020
Sorafenib Induces Apoptosis and Inhibits NF-κB-mediated Anti-apoptotic and Metastatic Potential in Osteosarcoma Cells.
    Anticancer research, 2021, Volume: 41, Issue:3

    Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Osteosarcoma; Sorafenib

2021
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
    Oncotarget, 2017, May-09, Volume: 8, Issue:19

    Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Disease Models, Animal; DNA; Doxorubicin; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Osteosarcoma; Phenylurea Compounds; RNA; Sorafenib; Xenograft Model Antitumor Assays

2017
A typical presentation of a hepatocellular carcinoma in a middle-aged patient.
    BMJ case reports, 2017, Aug-21, Volume: 2017

    Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Bone Neoplasms; Carcinoma, Hepatocellular; Clavicle; Fatal Outcome; Fractures, Bone; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib

2017
Sorafenib in patients with progressed and refractory bone tumors.
    Medical oncology (Northwood, London, England), 2018, Aug-16, Volume: 35, Issue:10

    Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Humans; Male; Retrospective Studies; Sorafenib; Young Adult

2018
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Child; Drug Resistance, Neoplasm; Humans; Male; Mutation; Osteosarcoma; Prognosis; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sorafenib

2019
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
    Acta clinica Belgica, 2020, Volume: 75, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Adenoid Cystic; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Pericardium; Pleural Neoplasms; Progression-Free Survival; Retrospective Studies; Salivary Gland Neoplasms; Sorafenib

2020
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?.
    Oncology, 2013, Volume: 84 Suppl 1

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Ethiodized Oil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Retrospective Studies; Sorafenib; Survival Rate

2013
Case of sorafenib-induced thyroid storm.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16

    Topics: Adrenal Gland Neoplasms; Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Biomarkers; Bone Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Heart Arrest; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Muscle Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Respiratory Aspiration; Sorafenib; Thyroid Crisis; Thyroid Hormones

2013
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013, Volume: 71, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid

2013
[Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Humans; Imidazoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Zoledronic Acid

2013
Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
    Oncology reports, 2014, Volume: 31, Issue:3

    Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Oligonucleotide Array Sequence Analysis; Oncogene Proteins v-fos; Osteosarcoma; Phenylurea Compounds; Receptors, CXCR4; S100 Calcium-Binding Protein A4; S100 Proteins; Sorafenib; Transcriptome

2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    European journal of endocrinology, 2014, Volume: 170, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome

2014
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    European urology, 2014, Volume: 66, Issue:3

    Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid

2014
Response to sorafenib treatment in advanced metastatic thyroid cancer.
    Arquivos brasileiros de endocrinologia e metabologia, 2014, Volume: 58, Issue:1

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; Follow-Up Studies; Heart Failure; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome

2014
RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?
    Oncology, 2015, Volume: 88, Issue:4

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Denosumab; Drug Resistance, Neoplasm; Humans; Male; Niacinamide; Osteosarcoma; Phenylurea Compounds; Prognosis; RANK Ligand; Remission Induction; Salvage Therapy; Sorafenib

2015
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
    Journal of pediatric surgery, 2015, Volume: 50, Issue:9

    Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pneumothorax; Sarcoma, Ewing; Sarcoma, Synovial; Sorafenib; Wilms Tumor; Young Adult

2015
Sorafenib-Sunitinib Sequence: The Jury Is Out.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2015
Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 66, Issue:1

    Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Cervical Cord; Chemoembolization, Therapeutic; Gamma Rays; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Unknown Primary; Niacinamide; Pelvic Bones; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed

2015
Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo.
    Scientific reports, 2015, Oct-21, Volume: 5

    Topics: Animals; Apoptosis; Bone Neoplasms; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Humans; Mice; Mouth Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays

2015
Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
    Cellular oncology (Dordrecht), 2016, Volume: 39, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Risk Factors; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult

2016
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
    Pediatric nephrology (Berlin, Germany), 2016, Volume: 31, Issue:6

    Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrexate; Nephrotic Syndrome; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proteinuria; Remission, Spontaneous; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Withholding Treatment

2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    European urology, 2016, Volume: 70, Issue:6

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden

2016
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
    World journal of gastroenterology, 2016, Jul-07, Volume: 22, Issue:25

    Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sirolimus; Sorafenib

2016
Choroidal metastasis from papillary thyroid cancer: An unusual feature of a common disease.
    Annales d'endocrinologie, 2017, Volume: 78, Issue:1

    Topics: Antineoplastic Agents; Bone Neoplasms; Choroid Neoplasms; Female; Goiter, Nodular; Humans; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy

2017
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: Adolescent; Animals; Antineoplastic Agents; Biological Therapy; Bone Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; Molecular Targeted Therapy; Necrosis; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein Kinase Inhibitors; Salmonella typhimurium; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays

2017
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.
    BioMed research international, 2017, Volume: 2017

    Topics: Bone Neoplasms; Carcinoma, Renal Cell; Demography; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib

2017
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome

2009
The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
    Research in veterinary science, 2010, Volume: 88, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bone Neoplasms; Caspase 3; Cell Count; Cell Line, Tumor; Dog Diseases; Dogs; Flow Cytometry; Ki-67 Antigen; Microscopy, Electron, Transmission; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib

2010
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2010
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:1

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Schistosomiasis; Skin Neoplasms; Soft Tissue Neoplasms; Sorafenib; Thyroid Neoplasms

2010
Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
    International journal of clinical oncology, 2009, Volume: 14, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Immunosuppressive Agents; Incidental Findings; Interferon-alpha; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiotherapy, Adjuvant; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid

2009
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 67, Issue:2

    Topics: Antineoplastic Agents; Asian People; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
[Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Interleukin-2; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Pain; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib

2010
Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.
    Journal of surgical oncology, 2010, Dec-01, Volume: 102, Issue:7

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Cyclin D1; Extracellular Signal-Regulated MAP Kinases; Humans; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Signal Transduction; Sorafenib

2010
Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Female; Humans; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Xenograft Model Antitumor Assays

2011
Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Urologic oncology, 2013, Volume: 31, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate

2013
Severe sorafenib-induced hand-foot skin reaction.
    Dermatology online journal, 2011, May-15, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Disease Progression; Drug Eruptions; Fatal Outcome; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib

2011
Hepatocellular carcinoma presenting with multiple bone and soft tissue metastases and atypical cytomorphological features--a rare case report.
    Diagnostic cytopathology, 2013, Volume: 41, Issue:7

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Radiography, Abdominal; Rare Diseases; Soft Tissue Neoplasms; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome

2013
Multiple cutaneous metastatic chordomas from the sacrum.
    Journal of the American Academy of Dermatology, 2012, Volume: 66, Issue:6

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Chordoma; Female; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sacrum; Skin Neoplasms; Sorafenib

2012
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C-Reactive Protein; Carcinoma, Renal Cell; Confidence Intervals; Female; Humans; Hyponatremia; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocytosis; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Severity of Illness Index; Sodium; Sorafenib; Sunitinib

2012
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Transplant international : official journal of the European Society for Organ Transplantation, 2012, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome

2012
Editorial comment from Dr Saito to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2012
Editorial comment from Dr Vázquez-Alonso and Dr Puche-Sanz to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:12

    Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib

2012
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
    British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Osteonecrosis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome

2012
[A case of hepatocellular carcinoma treated by resection of metachronous rib metastasis after primary hepatectomy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Ribs; Sorafenib

2012
Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
    European urology, 2007, Volume: 52, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2007
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
    Praxis, 2007, May-02, Volume: 96, Issue:18

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed

2007
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate

2007